Hormone-resistant prostate cancer, or castrate-resistant prostate cancer (CRPC), is cancer that continues to grow despite androgen (hormone)-deprivation therapy (ADT), that is, therapy that lowers the level of testosterone (an orchiectomy, a luteinizing-hormone releasing hormone [LHRH] agonist, or LHRH antagonist). Hormone-resistant prostate cancer may present as any combination of the following: Continuous rise in serum levels of prostate-specific antigen (PSA), progression of preexisting cancer, or appearance of new metastases.
Treatment options for hormone-resistant prostate cancer include:
- Maintaining castrate levels of testosterone through continued ADT
- Second-line hormonal therapies to lower PSA levels (for men naïve to chemotherapy but who are at high risk of developing metastases)
- Abiraterone acetate plus prednisone